Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00730522).
- Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan: Complete Statistical AnalysisIndependent statistical analysis of Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis: primary endpoint results, effect estimate…
- Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD): Complete Statistical AnalysisIndependent statistical analysis of Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule): primary endpoint results, effect estimate with confidence…
- Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine: primary endpoint results, effect…
- Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second…
- Safety and Immunogenicity of a Booster Dose of GSK Biological’s Boostrix-Polio Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03055000).
- Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to
- Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02445963).
- Safety and Immunogenicity of CJCV2 With and Without ALFQ: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of CJCV2 With and Without ALFQ: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05500417).
- Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®: primary endpoint results, effect estimate with…
- Safety and Immunogenicity of Different Schedules of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety and Immunogenicity of GSK’s Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib Vaccine (GSK217744): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years: primary endpoint results, effect estimate with…
- Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above: primary endpoint…
- Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01147068).
- Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…